Samsung Bioepis and Takeda signed a strategic collaboration agreement to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The first therapeutic candidate, TAK-671, is intended to treat severe acute pancreatitis. The risk-sharing partnership brings together Samsung Bioepis’ agile biologics development platform with Takeda’s best-in-class experts in drug development.

Takeda also closed a commercial license agreement (CLA) with Selexis SA to access the high-performance research cell banks (RCBs) developed using the Selexis SUREtechnology Platform™, a mammalian cell line-based protein expression platform that facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein including those that are difficult to express in other systems. It also provides seamless integration of the biologics and vaccine development continuum, spanning discovery to commercialization.